Lifevantage Corp Stock Price, News & Analysis

LifeVantage (Nasdaq: LFVN) has completed a successful 12-week human clinical trial evaluating its innovative GLP-1 system for weight management. The study, involving 60 participants, assessed the system's impact on weight management, food cravings, and overall well-being. Participants were divided into three groups: product system alone, product system with diet and exercise guidance, and a control group.

Lisa Barnes, VP of Research, Development & Regulatory, expressed confidence in the system's ability to address weight management challenges through natural activation of GLP-1. The results will be shared at Market Connect in Kansas City, October 11-12, 2024, where the system will be revealed. CEO Steve Fife emphasized the company's commitment to delivering products that activate the body's natural processes. This trial, along with a recently completed in vitro study, marks a significant milestone in LifeVantage's efforts to expand its portfolio of activation products supporting cellular health.

LifeVantage (Nasdaq: LFVN) has announced positive in vitro results for its new GLP-1 system, designed to enhance weight management. The study, conducted on specialized L-cells in the colon, examined key genes involved in GLP-1 production and regulation. The two-product system showed synergistic gene activation, significantly increasing GLP-1 production through direct L-cell activation and gut microbiome optimization.

The research revealed downregulation of DPP-4 gene expression, allowing for more GLP-1 availability in the body. LifeVantage plans to introduce this innovative system in October, targeting new consumers and expanding market opportunities for its Consultants. The company emphasizes that these products are designed to activate optimal health processes at the cellular level, leveraging their unique Activation approach.

LifeVantage (Nasdaq: LFVN), a leading health and wellness company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY. Steve Fife, President and CEO, and Carl Aure, CFO, will represent the company, meeting with investors and delivering a presentation on Tuesday, September 10, 2024, at approximately 2:00 p.m. Eastern Time.

A live webcast of the presentation will be available on the company's Investor Relations website. The webcast replay will be accessible for about 90 days after the event. This conference participation highlights LifeVantage's commitment to engaging with investors and showcasing its products designed to activate optimal health processes at the cellular level.

LifeVantage (Nasdaq: LFVN) has announced the permanent addition of AXIO® Lemonade to its product lineup. Previously available as a -time offering, this fan-favorite flavor is now a permanent part of the AXIO energy drink range. AXIO Lemonade offers clean, sustained energy and focus through a nootropic blend of vitamins, minerals, and phytonutrients, without excess calories, sugar, or artificial additives.

The product aims to improve mental sharpness, elevate mood, and enhance stress resilience. CEO Steve Fife emphasized that this move represents LifeVantage's commitment to providing effective energy solutions that support an active lifestyle while delivering mental focus and stress resilience.

LifeVantage (Nasdaq: LFVN), a prominent health and wellness company, has announced a quarterly cash dividend of $0.04 per share of common stock. The dividend will be paid on September 17, 2024, to stockholders of record at the close of business on September 9, 2024. LifeVantage specializes in products designed to activate optimal health processes at the cellular level. This dividend declaration demonstrates the company's commitment to returning value to its shareholders and may indicate confidence in its financial stability and future prospects.

LifeVantage (Nasdaq: LFVN) reported financial results for Q4 and fiscal year 2024. Key highlights:

- Q4 revenue: $48.9 million, down 9.8% YoY
- FY2024 revenue: $200.2 million, down 6.2% YoY
- Q4 net income per diluted share: $0.10, down from $0.15 YoY
- FY2024 net income per diluted share: $0.23, up from $0.20 YoY
- FY2024 adjusted EBITDA: $17.0 million, up 44.7% YoY
- Strong balance sheet with $16.9 million cash and no debt

The company declared a cash dividend of $0.04 per share. For FY2025, LifeVantage projects revenue of $200-210 million, adjusted EBITDA of $18-21 million, and adjusted EPS of $0.70-$0.80.

LifeVantage (Nasdaq: LFVN) has announced the appointment of Rajendran Anbalagan to its Board of Directors, effective immediately. This strategic move follows a comprehensive search for a candidate with transformational digital skills. Mr. Anbalagan brings extensive technology experience and a deep understanding of leveraging digital tools for operational excellence.

Simultaneously, Erin Brockovich has resigned from the Board after five years of service to make room for Mr. Anbalagan. The company expressed gratitude for Ms. Brockovich's contributions, citing her diverse legal and business background and renowned advocacy experience as valuable assets during her tenure.

LifeVantage (Nasdaq: LFVN) recently hosted its exclusive Rise Retreat in Park City, UT, from August 22-25, 2024. The event brought together top enrolling Independent Consultants for a weekend of leisure, adventure, and strategic collaboration. Attendees received an exclusive preview of LifeVantage's innovative weight management products, set to launch in October. These products are designed to activate natural production of the GLP-1 hormone, reduce food noise, and support healthy weight goals.

Consultants who earned the trip were given the opportunity to try the new weight management system ahead of its official launch. The retreat encouraged collaboration, with participants brainstorming strategies to build excitement over the next six weeks. The full details of the new products will be unveiled at Market Connect in Kansas City, MO, on October 11-12, 2024.

LifeVantage (Nasdaq: LFVN), a health and wellness company, has announced it will release its fourth quarter and full fiscal year 2024 financial results on August 28, 2024, after the stock market closes. The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day.

Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 internationally. A telephone replay will be available until September 11, 2024. Additionally, a live webcast will be accessible on the company's Investor Relations website, with an archive available for approximately 30 days.